Home       Market Dynamics     Macro Trends     Sector Trends     Company Insights     AI Investing     Strategies     Sign Up     Login         

Bristol-Myers Squibb (BMY) Stock Price Prediction and News Highlight
Mon. Oct 12, 2026

One Week Return: -2.06%, One Month Return: -9.49%, Three Month Return: 0.03%

Sector: Pharmaceuticals

Bristol-Myers Squibb showcases a robust potential for product growth, particularly with the performance of Reblozyl and the successful outcomes from their Zenbexus blood cancer treatment. The company continues to demonstrate advancements in cancer treatments, positively influencing patient outcomes and bolstering its reputation in the healthcare sector. Additionally, recent positive clinical trial results across multiple therapies signify a strong future for their product pipeline. Overall, optimism prevails as the firm pushes forward with impactful healthcare innovations.

The price action of Bristol-Myers Squibb (BMY) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The trend sentiment at -1.9 is very bearish. The market sentiment at 0.2 is modestly bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next. There is no clear direction for BMY since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 0.7, and the negative at -0.5 on 2026-10-12. The forces of Stock Price Trend (-1.9), Market Risk Appetite (-0.5), and Valuation Sentiment (-0.4) will drive down the price. The forces of Sector Price Trend (0.3), Price Level Sentiment (1), Option Sentiment (1.5), and Sentiment towards Fundamentals (1.7) will drive up the price.

The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band.

Earning Release: 2026-10-29 06:30, EPS: $5.93, P/E: 9.71

Sign up to reveice notifications on Market Movers
BMY
DateAttentionPriceStdDevPrice
Level
RSIHourly
RSI
Change10 Day
Trend
Trend
Sentiment
Hourly
Trend
Sentiment
Hourly
StdDev
Market
Sentiment
ActionPFund.News
Sentiment
2026-10-121%(0.1%)      57.58 3.28%    -3    28   33   -2.59%    -1.15% -1.9    -1    1.1%    0.3    Short    70% 1.7    3.5   
2026-10-110%(0%)    -1.4    -1    0          1.7    -1   
2026-10-100%(0%)    -1.4    -1    0.7          1.4    -1   
2026-10-090%(0%)      59.11 2.86%    9    31   54   -0.76%    -0.49% -1.4    -0.3    0.5%    1.5    Short    55% 2    -1   
2026-10-080%(0%)      59.56 2.69%    9    34   47   -0.2%    -0.33% -0.9    0.2    0.5%    1.1    Wait    50% 1.7    -1   
2026-10-070%(0%)      59.68 2.61%    6    32   61   0.16%    -0.49% -1.5    -0.2    0.7%    1.2    Short    55% 1.5    6   
2026-10-060%(0%)      59.59 2.52%    -2    31   72   1.35%    -0.48% -1.5    0.2    1.3%    0.8    Wait    50% 1.3    -1   
2026-10-050%(0%)      58.79 2.7%    -16    25   34   -3.86%    -0.64% -2.3    -0.7    1.9%    0.8    Short    70% 1.2    -1   
2026-10-040%(0%)    -1.1    -0.7    0.1          1.4    -1   
2026-10-030%(0%)    -1.1    -0.7    0.5          1.5    -1   
 
Short is the preferred trading strategy with 70% chance of being right. Both trend sentiment and hourly trend are very weak.

Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position.

Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force.

  Analysis
● Bristol Myers Squibb (BMY) – Equity Research Report Fri. Mar 13, 2026

2026-10-12 17:07:19 Bristol-Myers Squibb's successful trial outcomes indicate a strong potential for future growth and investments in new treatments.
2026-10-12 17:07:19 The presence of competing therapies and mixed results from rival products creates a challenging environment for Bristol-Myers Squibb.
2026-10-12 17:07:19 Despite positive trial results, concerns regarding generic competition and stock valuation are causing some investors to exercise caution.
2026-10-12 17:07:19 The company has reported positive outcomes from multiple Phase 3 trials, which generally boost investor confidence and highlight potential growth in their product pipeline.
2026-10-12 17:07:19 The stock price of Bristol-Myers Squibb has shown significant volatility, experiencing declines even in light of positive trial results, indicating mixed investor sentiments.
2026-10-12 15:49:25 Some articles mention concerns regarding 'confounding' trial results, which could impact the stock and overall company outlook negatively.
2026-10-12 15:49:25 The stock performance of Bristol Myers Squibb shows significant fluctuations based on trial results, reflecting investor interest and market responsiveness.
2026-10-12 15:49:25 Bristol Myers Squibb is making significant investments in the development of radiopharmaceutical cancer drugs, signaling a strong commitment to expanding their product pipeline.
2026-10-12 15:49:25 The articles highlight positive results from Bristol Myers Squibb's drug trials for treating neuroendocrine tumors and lung disease, indicating advancements in their pharmaceutical development.


About   Contact Us  
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA